

AMENDMENTS TO THE CLAIMS

1 (Previously Presented). A method for treating breast cancer, or colon cancer, or prostate cancer in a patient comprising

administering to the patient an effective amount of a compound comprising perfluorooctanoic acid, or a salt of perfluorooctanoic acid, or an ester formed between perfluorooctanoic acid and an alcohol of formula R^1OH , or an ester formed between perfluorooctanoic acid and a thiol of formula R^1SH , wherein R^1 consists essentially of C_{1-16} alkyl groups or C_{6-10} acryl groups.

2 to 5 (Canceled).

6 (Previously Presented). A method comprising providing a compound comprising perfluorooctanoic acid, or a salt of perfluorooctanoic acid, or an ester thereof formed between perfluorooctanoic acid and an alcohol of formula R^1OH , or an ester formed between perfluorooctanoic acid and a thiol of formula R^1SH , wherein R^1 consists essentially of C_{1-16} alkyl groups or C_{6-10} acryl groups, and

treating breast cancer, or colon cancer, or prostate cancer using the compound.

7 (Withdrawn). The method of claim 1 wherein the patient is in need of an increase in PPAR activity and the compound is a PPAR agonist.

8 (Withdrawn). The method of claim 7 wherein the PPAR is $PPAR\alpha$ or $PPAR\gamma$.

9 (Canceled).

10 (Withdrawn). The method of claim 1 wherein the patient is in need of reduction of body mass or prevention of increase in body mass, and/or in need of reduction of plasma insulin, plasma glucose, plasma triglycerides and/or plasma cholesterol.

11 – 12 (Canceled).

13 (Previously Presented). The method of claim 1 wherein the perfluorooctanoic acid comprises at least 50% linear perfluorooctanoic acid.

14 (Withdrawn). The method of claim 1

wherein the compound is or comprises a perfluoroheptanoic acid or salt or ester thereof.

15 (Withdrawn). The method of claim 1

wherein the compound is a perfluoropentanoic acid or salt or ester thereof.

16 (Canceled).

17 (Withdrawn). A screening method for identifying a drug-like compound or lead compound for the development of a drug-like compound comprising

exposing a mammal to a compound as defined in claim 1 or derivative thereof, and measuring at least one of the plasma insulin, glucose, cholesterol, triglyceride, bodyweight, and lipid or eicosanoid status or function of the mammal.

18 (Withdrawn) . The method of claim 17, further comprising the step of selecting a compound on exposure to which the plasma insulin, glucose, cholesterol and/or triglyceride level of the mammal is changed or reduced, and/or bodyweight or bodyweight increase of the mammal is changed or reduced.

19 (Withdrawn). A screening method for identifying a drug-like compound or lead compound for the development of a drug-like compound comprising

exposing a compound as defined in claim 1 or derivative thereof to a PPAR polypeptide, and

measuring at least one of binding of the compound to the PPAR polypeptide or the change in the activity of the PPAR polypeptide.

20 (Withdrawn). A screening method for identifying a drug-like compound or lead compound for the development of a drug-like compound comprising

exposing a compound as defined in claim 1 or derivative thereof to a lipid metabolising or binding entity, and

measuring at least one of the binding of the compound to the lipid metabolising or binding entity or the change in the activity of the lipid metabolising or binding entity.

21 (Withdrawn) . A screening method for identifying a drug-like compound or lead compound for the development of a drug-like compound comprising

exposing a cell to a compound as defined in claim 1, and

measuring at least one of the phenotype and the eicosanoid biosynthesis of the cell.

22 (Withdrawn). The method of claim 21, further comprising

the step of selecting a compound on exposure to which at least one of the phenotype of the cell or the eicosanoid biosynthesis of the cell is changed.

23 (Withdrawn). The method of claim 1 wherein the compound is identified or identifiable by the screening method of claim 17.

24 (Canceled).

25 (Withdrawn). A food product comprising a foodstuff, and a compound as defined in claim 1.

26 (Withdrawn). A kit of parts of screening system comprising a library of compounds each as defined in claim 1, and a PPAR polypeptide or polynucleotide encoding a PPAR polypeptide, and/or a test mammal.

27 (Withdrawn). A kit of parts of screening system comprising a library of compounds each as defined in claim 1, and at least one of a lipid metabolising or binding entity or a polynucleotide encoding a lipid metabolising or binding entity.

28 (Canceled).

29 (Withdrawn). A method as in claim 1 wherein the PPAR activity is PPAR α activity.

30 (Canceled).

31 (Withdrawn). A method as in claim 6 wherein the PPAR activity is PPAR α activity.

32 (Withdrawn). A method as in claim 6 wherein the medicament is for the treatment of a patient in need of an increase in PPAR activity and the compound is a PPAR agonist.

33 (Canceled).

34 (Withdrawn). The method of claim 1 wherein the compound is identified or identifiable by the screening method of claim 19.

35 (Withdrawn). The method of claim 1

wherein the compound is identified or identifiable by the screening method of claim 20.

36 (Withdrawn). The method of claim 1

wherein the compound is identified or identifiable by the screening method of claim 21.

37 (Withdrawn). A food product as in claim 25

wherein the foodstuff is not laboratory rodent feed.

38 (Previously Presented). The method of claim 1

wherein R¹ consists essentially of C₁₋₁₀ alkyl groups.

39 (Previously Presented). The method of claim 1

wherein R¹ consists essentially of C₁₋₆ alkyl groups.

40 (Previously Presented). The method of claim 6

wherein R¹ consists essentially of C₁₋₁₀ alkyl groups.

41 (Previously Presented). The method of claim 6

wherein R¹ consists essentially of C₁₋₆ alkyl groups.

42 (Previously Presented). The method of claim 6

wherein the perfluorooctanoic acid comprises more than 75% linear perfluorooctanoic acid.